Overview: an iPS cell stock at CiRA
Abstract Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a...
Main Authors: | Masafumi Umekage, Yoshiko Sato, Naoko Takasu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Inflammation and Regeneration |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41232-019-0106-0 |
Similar Items
-
CiRA iPSC seed stocks (CiRA's iPSC Stock Project)
by: Tadaaki Hanatani, et al.
Published: (2021-01-01) -
HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
by: Sunao Sugita, et al.
Published: (2020-07-01) -
Generation of hypoimmunogenic T cells from genetically engineered allogeneic iPS cells for off-the-shelf cancer immunotherapy
by: Wang, Bo
Published: (2021) -
iPS cells generation: an overview of techniques and methods
by: Telpalo-Carpio SA, et al.
Published: (2013-04-01) -
iPS Cells—The Triumphs and Tribulations
by: Riddhi Sharma
Published: (2016-06-01)